Zobrazeno 1 - 10
of 438
pro vyhledávání: '"Kiat, Ruxrungtham"'
Autor:
Thanyawee Puthanakit, Eakachai Prompetchara, Sivaporn Gatechompol, Chutitorn Ketloy, Arunee Thitithanyanont, Anan Jongkaewwattana, Supranee Buranapraditkun, Sasiwimol Ubolyam, Stephen J. Kerr, Jiratchaya Sophonphan, Tanakorn Apornpong, Wonngarm Kittanamongkolchai, Sarawut Siwamogsatham, Somchai Sriplienchan, Kanitha Patarakul, Tuangtip Theerawit, Pathariya Promsena, Rapisa Nantanee, Siwaporn Manomaisantiphap, Sarun Chokyakorn, Lina Hong, Mijo Samija, David C. Montefiori, Hongmei Gao, Amanda Eaton, Wassana Wijagkanalan, Mohamad-Gabriel Alameh, Drew Weissman, Kiat Ruxrungtham, ChulaVac001-Phase 2 study team
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-10 (2024)
Abstract ChulaCov19 mRNA vaccine demonstrated promising phase 1 results. Healthy adults aged 18–59 years were double-blind randomised 4:1 to receive two intramuscular doses of ChulaCov19 50 µg or placebo. Primary endpoints were safety and microneu
Externí odkaz:
https://doaj.org/article/54f54eeb03db4688a4ae18fe00c232c3
Autor:
Eakachai Prompetchara, Chutitorn Ketloy, Mohamad-Gabriel Alameh, Kittipan Tharakhet, Papatsara Kaewpang, Nongnaphat Yostrerat, Patrawadee Pitakpolrat, Supranee Buranapraditkun, Suwimon Manopwisedjaroen, Arunee Thitithanyanont, Anan Jongkaewwattana, Taweewan Hunsawong, Rawiwan Im-Erbsin, Matthew Reed, Wassana Wijagkanalan, Kanitha Patarakul, Teerasit Techawiwattanaboon, Tanapat Palaga, Kieu Lam, James Heyes, Drew Weissman, Kiat Ruxrungtham
Publikováno v:
Nature Communications, Vol 14, Iss 1, Pp 1-15 (2023)
Abstract Establishment of an mRNA vaccine platform in low- and middle-income countries (LMICs) is important to enhance vaccine accessibility and ensure future pandemic preparedness. Here, we describe the preclinical studies of “ChulaCov19”, a SAR
Externí odkaz:
https://doaj.org/article/8ef9ba85430b45f099ca23e47323d308
Autor:
Pupe Sudsila PhD, Sirinya Teeraananchai PhD, Sasisopin Kiertiburanakul MD, Cheewanan Lertpiriyasuwat MD, Rattaphon Triamwichanon MD, Sivaporn Gatechompol MD, Opass Putcharoen MD, Ploenchan Chetchotisakd MD, Anchalee Avihingsanon MD, PhD, Stephen J Kerr PhD, Kiat Ruxrungtham MD
Publikováno v:
Journal of the International Association of Providers of AIDS Care, Vol 22 (2023)
This study aimed to assess second-line antiretroviral therapy (ART) outcomes in a National HIV Treatment program. People living with HIV aged ≥18 years initiating first-line ART who switched to second-line protease inhibitor-based regimens from Jan
Externí odkaz:
https://doaj.org/article/faa7f06e525941fdbd5c33d5e2a31750
Autor:
Theerapat Phoka, Naruchit Thanuthanakhun, Peerapat Visitchanakun, Narintorn Dueanphen, Nisha Wanichwecharungruang, Asada Leelahavanichkul, Tanapat Palaga, Kiat Ruxrungtham, Supason Wanichwecharungruang
Publikováno v:
Vaccine: X, Vol 15, Iss , Pp 100398- (2023)
Although vaccine administration by microneedles has been demonstrated, delivery reliability issues have prevented their implementation. Through an ex vivo porcine skin experiment, we show visual evidence indicating that detachable dissolvable microne
Externí odkaz:
https://doaj.org/article/6484d83cca5446d3862b3112ea69af84
Autor:
Seth C Inzaule, Mark J Siedner, Susan J Little, Santiago Avila-Rios, Alisen Ayitewala, Ronald J Bosch, Vincent Calvez, Francesca Ceccherini-Silberstein, Charlotte Charpentier, Diane Descamps, Susan H Eshleman, Joseph Fokam, Lisa M Frenkel, Ravindra K Gupta, John P A Ioannidis, Pontiano Kaleebu, Rami Kantor, Seble G Kassaye, Sergei L Kosakovsky Pond, Vinie Kouamou, Roger D Kouyos, Daniel R Kuritzkes, Richard Lessells, Anne-Genevieve Marcelin, Lawrence Mbuagbaw, Brian Minalga, Nicaise Ndembi, Richard A Neher, Roger Paredes, Deenan Pillay, Elliot G Raizes, Soo-Yon Rhee, Douglas D Richman, Kiat Ruxrungtham, Pardis C Sabeti, Jonathan M Schapiro, Sunee Sirivichayakul, Kim Steegen, Wataru Sugiura, Gert U van Zyl, Anne-Mieke Vandamme, Annemarie M J Wensing, Joel O Wertheim, Huldrych F Gunthard, Michael R Jordan, Robert W Shafer
Publikováno v:
PLoS Medicine, Vol 20, Iss 9, p e1004293 (2023)
• Human immunodeficiency virus (HIV) drug resistance has implications for antiretroviral treatment strategies and for containing the HIV pandemic because the development of HIV drug resistance leads to the requirement for antiretroviral drugs that
Externí odkaz:
https://doaj.org/article/c16a34440b374c53938659e86b679144
Autor:
Poonsook Keelapang, Romchat Kraivong, Rojjanaporn Pulmanausahakul, Rungtawan Sriburi, Eakachai Prompetchara, Jutamart Kaewmaneephong, Nicha Charoensri, Pattarakul Pakchotanon, Thaneeya Duangchinda, Piyanan Suparattanagool, Prasit Luangaram, Promsin Masrinoul, Juthathip Mongkolsapaya, Gavin Screaton, Kiat Ruxrungtham, Prasert Auewarakul, Sutee Yoksan, Prida Malasit, Chunya Puttikhunt, Chutitorn Ketloy, Nopporn Sittisombut
Publikováno v:
Microbiology Spectrum, Vol 11, Iss 4 (2023)
ABSTRACT Humans infected with dengue virus (DENV) acquire long-term protection against the infecting serotype, whereas cross-protection against other serotypes is short-lived. Long-term protection induced by low levels of type-specific neutralizing a
Externí odkaz:
https://doaj.org/article/72aa1c4bba1f47fa9109f0840c02df42
Autor:
Emmanuelle Papot, Simone Jacoby, Dona Arlinda, Anchalee Avihingsanon, Iskandar Azwa, Margaret Borok, Dannae Brown, Mohamed Cissé, Sounkalo Dao, Nnakelu Eriobu, Richard Kaplan, Muhammad Karyana, Nagalingeswaran Kumarasamy, Johnnie Lee, Marcelo H. Losso, Gail V. Matthews, Leonardo Perelis, Carmen Perez-Casas, Kiat Ruxrungtham, Melynda Watkins, H. Clifford Lane, Anthony Kelleher, Matthew Law, Mark N. Polizzotto
Publikováno v:
HIV Research & Clinical Practice, Vol 23, Iss 1, Pp 37-46 (2022)
A rapidly changing landscape of antiretrovirals and their procurement at scale has permitted the evaluation of new optimised second-line antiretroviral therapy (ART) in low- and middle-income countries. D2EFT is an open-label randomised controlled no
Externí odkaz:
https://doaj.org/article/1e534f2c23af4fa8b68b25301742d28b
Autor:
Kiat Ruxrungtham
Publikováno v:
International Journal of Infectious Diseases, Vol 130, Iss , Pp S45-S46 (2023)
COVID-19 mRNA vaccines: COVID-19 pandemic has made an extraordinary impact on global vaccine technology platform developments. Never in human history have there at least 6 vaccine platforms including: inactivated, protein subunit, VLP and other 3 new
Externí odkaz:
https://doaj.org/article/4c39a3db43a2465681765ebb464da1c4
Autor:
Tawee Chotpitayasunondh, Dale Andrew Fisher, Po-Ren Hsueh, Ping-Ing Lee, Katya Nogales Crespo, Kiat Ruxrungtham
Publikováno v:
International Journal of Translational Medicine, Vol 2, Iss 3, Pp 275-308 (2022)
This paper provides a comprehensive summary of evidence to explore and position the role of serology testing in the context of coronavirus disease 19 (COVID-19) immunization and policy response in the Asia-Pacific (APAC) region. The document builds o
Externí odkaz:
https://doaj.org/article/8811fbc9cad7463588d7e4f7d658a44b
Autor:
Sirinya Teeraananchai, Stephen J. Kerr, Kiat Ruxrungtham, Panthep Khananuraksa, Thanyawee Puthanakit
Publikováno v:
Journal of the International AIDS Society, Vol 26, Iss 3, Pp n/a-n/a (2023)
Introduction The Thai National AIDS programme (NAP) treatment guidelines have recommended rapid antiretroviral therapy (ART) initiation, regardless of CD4 count since 2014. We assessed treatment outcomes among youth living with HIV (YLHIV), initiatin
Externí odkaz:
https://doaj.org/article/9a4ef91ca051409db579c5570b19e97d